ArticleHuman genomics2025
Genome-wide methylation profiles of primary and matched distant metastasis: insights from the Dutch Early-Stage melanoma (D-ESMEL) study.
Article in Human genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly-stage (stage I-II) cutaneous melanoma accounts for the majority of melanoma diagnoses. However, more than 40% of patients who die due to melanoma were initially diagnosed with an early-stage melanoma. This highlights the current limitations of the Tumor Node Metastasis (TNM) staging and shows that additional biomarkers, prognostic for distant metastasis, need to be identified.
methodsThe aim of this study was to identify prognostic genome-wide methylation markers of metastasized primary early-stage melanomas and retrieving biological insights from its matched distant metastasis. We selected 45 samples from the Dutch Early-Stage Melanoma (D-ESMEL) study, representing case-control sets where the primary melanoma of each metastatic case (n = 15) is matched to a primary melanoma of a control (n = 15) based on known clinical risk factors. Matched distant metastasis (n = 15) were also retrieved. Laser capture microdissection was performed to isolate the tumor tissue, where after a genome-wide methylated DNA sequencing (MeD-seq) was conducted. After quality control, a total of 30 samples were retained for analysis, including 11 controls, 9 cases, and 10 metastatic samples. Differentially methylated regions (DMR) between primary tumors of the cases-control sets and the tumor of the primary case and its metastasis were tested using Chi-squared test with a genome-wide sliding window analysis, as well as a paired t-test in predefined promotor, gene body, and CpG-island regions.
resultsMeD-seq analyses did not reveal prognostic methylation markers in primary melanomas, which have additional prognostic value on top of known clinical risk factors after correction for multiple testing. However, exploratory analysis before correction revealed eight protein coding genes with the largest methylation difference between primary melanomas of patients with and without metastasis and between primary melanomas and matched distant metastasis: CYP2E1, PTPRN2, CHCHD2, NDRG2, EDN2, GC, USP17L1, and SERPINB8.
conclusionThis study found 8 genes that have been implicated in primary tumors or metastasis of other cancers which require further investigation into their involvement of metastasis in melanoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.